RT Journal Article
SR Electronic
T1 Both HFrEF and HFpEF Should be Included in Calculating CHA2DS2–VASc score: a Taiwanese Longitudinal Cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.25.23297579
DO 10.1101/2023.10.25.23297579
A1 Cheng, Chien-Chien
A1 Huang, Pang-Shuo
A1 Chen, Jien-Jiun
A1 Chiu, Fu-Chun
A1 Chang, Sheng-Nan
A1 Wang, Yi-Chih
A1 Wu, Cho-Kai
A1 Hwang, Juey-Jen
A1 Tsai, Chia-Ti
YR 2023
UL http://medrxiv.org/content/early/2023/10/26/2023.10.25.23297579.abstract
AB Background Congestive heart failure (CHF) in the context of AF-related stroke risk, was coined when it mainly referred to patients with left ventricular systolic dysfunction (HFrEF). However, the term now encompasses patients with preserved ejection fraction (HFpEF) as well. Given this change, it becomes essential to investigate the variation in stroke risk between atrial fibrillation (AF) patients with HFpEF and HFrEF for enhancing risk assessment and subsequent management strategies.Methods In a longitudinal study utilizing the National Taiwan University Hospital Integrated Medical Database (iMED), 8358 patients with AF were followed up for 10 years from January 2010 to December 2020 (mean follow-up 3.76 years). The study evaluated the risk of ischemic stroke, using Cox models adjusted for potential risk factors of AF-related stroke.Results Comparing AF patients of different CHF subgroups, HFpEF patients had a higher mean CHA2DS2–VASc score (4.08±1.502 vs. 3.83±1.571, p<0.001) and a higher risk of stroke during follow-up (HR 1.151 (1.013-1.308), p=0.031). In contrast, patients with HFrEF had a higher prevalence of myocardial infarction (MI) and coronary artery disease (CAD). After adjusting for other risk factors, there was no significant difference in the risk of new-onset stroke between HFpEF and HFrEF patients (HR 1.001 (0.877-1.142), p=0.994).Conclusion After adjusting for other risk factors of stroke, both HFpEF and HFrEF were found to have a similar risk of stroke in AF patients. Therefore, it is important to extend the criteria for “C” in the CHA2DS2–VASc score to include HFpEF patients. Prior to multivariable adjustment, HFpEF patients had a higher risk than those with HFrEF, likely due to their higher CHA2DS2–VASc score, indicating a greater prevalence of stroke-related comorbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by a grant from the National Science and Technology Council (110-2314-B-002-198-MY3).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol received approval from the Research Ethics Committee of the NTUH, and informed consent was waived given the retrospective nature of the study. Patient data with any identifying information was accessible only to the investigators and kept confidential in accordance with the approved protocol 200911002R and 202011019RINCI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRestrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.